DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells

Khodaei, Malihe; Rostamizadeh, Kobra; Taromchi, Amir Hossein; Monirinasab, Hannaneh; Fathi, Mojtaba

doi:10.1007/s12094-020-02507-3

Cited by 14 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-based drug delivery systems provide a concrete platform for effective and specific drug delivery in many diseases where other delivery systems have failed [ 19 , 34 ]. The advantages offered by the lipid delivery systems in carrying the active constituent to the site of action need to continuously be explored and established [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…6X loading dye (2 μ l) was mixed into each formulation sample, and the total solution was loaded into each well. The samples were electrophoresed at 100 V for approximately 30 min, and standardethidium bromide (EtBR) staining with UV fluorescent detection was employed, and the resultant image of the gel was captured using a GelDoc Go System (Bio-Rad Laboratories, Hercules, CA, USA) [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines

Vaidya

Jeengar²,

Wadaan

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Breast cancer is the most common cause of cancer mortality in Western nations, with a terrible prognosis. Many studies show that siRNA plays a role in the development of tumors by acting as a tumor suppressor and apoptosis inhibitor or both. siRNAs may be used as diagnostic and prognostic biomarkers in breast cancer. Antisurvivin siRNA was chosen as a therapeutic target in breast cancer treatment because it directly targets survivin, an inhibitor of apoptosis protein, that causes cell death. However, siRNA-based treatment has significant limitations, including a lack of tissue selectivity, a lack of effective delivery mechanisms, low cellular absorption, and the possibility of systemic toxicity. To address some of these issues, we provide a siRNA delivery method based on cationic lipids. In the recent past, cationic liposomes have displayed that they offer a remarkable perspective in proficient siRNA delivery. The presence of a positive charge plays a vital role in firm extracellular siRNA binding along with active intracellular siRNA separation and low biological adversities. Consequently, the methods for developing innovative cationic lipids through rendering and utilization of appropriate positive charges would certainly be helpful for benign and effective siRNA delivery. In the current study, an effort was made to synthesize a 3,4-dimethoxyaniline lipid (DMA) to improve the effectiveness and protection of successful siRNA delivery. DMA cationic lipid successfully delivered survivin siRNA that reduced the survivin mRNA expression, indicating the possibility of utilizing siRNA therapeutics for breast cancer. It is expected that this innovative quaternary amine-based liposome can open up new avenues in the process of developing an easy and extensively used platform for siRNA delivery. Cationic lipoplexes, a potential carrier system for siRNA-based therapies in the treatment of breast cancer, were proven by our data.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines

Vaidya

Jeengar²,

Wadaan

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Redox-sensitive nanoparticles have been modified with peptides to promote their internalization in cells and effectively suppress breast cancer progression [ 84 ]. The encapsulation efficiency of nanoparticles seems to be up to 95% [ 85 ] and they can mediate chemosensitivity via co-delivery of siRNA (KRAS) and anti-tumor drugs (gemcitabine) [ 86 ]. In the following sections, a mechanistic and in-depth discussion of using various siRNAs in PC therapy is provided.…”

Section: Sirnas: From Basic To Application In Cancer Therapymentioning

confidence: 99%

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Mirzaei

Gholami

Ang

et al. 2021

Cells

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the leading causes of death and is the fourth most malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for development of PC. Small interfering RNA (siRNA) is a powerful genetic tool that can bind to its target and reduces expression level of a specific gene. The various critical genes involved in PC progression can be effectively targeted using diverse siRNAs. Moreover, siRNAs can enhance efficacy of chemotherapy and radiotherapy in inhibiting PC progression. However, siRNAs suffer from different off target effects and their degradation by enzymes in serum can diminish their potential in gene silencing. Loading siRNAs on nanoparticles can effectively protect them against degradation and can inhibit off target actions by facilitating targeted delivery. This leads to enhanced efficacy of siRNAs in PC therapy. Moreover, different kinds of nanoparticles such as polymeric nanoparticles, lipid nanoparticles and metal nanostructures have been applied for optimal delivery of siRNAs that are discussed in this article. This review also reveals that how naked siRNAs and their delivery systems can be exploited in treatment of PC and as siRNAs are currently being applied in clinical trials, significant progress can be made by translating the current findings into the clinical settings.

show abstract

“…It has been reported that lipid‐polymer hybrid nanoparticles (LPHNP) could be utilized as siRNA carriers to mutate insulin‐resembling growth factor type I (IGF‐1R) gene increased expression in the MCF‐7 human mammary tumor cell unit. According to the latest report, cationic lipid based on dimethyldioctadecylammonium bromide (DDAB) and mPEG‐PCL copolymer hybrid nanoparticle represent a promising tool for effective siRNA delivery [40] . Combination of an artificial cationic lipid 1,2‐dimyristoyl‐3‐trimethylammonium‐propane (DMTAP) with a nanodisc (ND) provide another siRNA delivery vehicle.…”

Section: Cationic Lipids For Sirna Deliverymentioning

confidence: 99%

“…According to the latest report, cationic lipid based on dimethyldioctadecylammonium bromide (DDAB) and mPEG-PCL copolymer hybrid nanoparticle represent a promising tool for effective siRNA delivery. [40] Combination of an artificial cationic lipid 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP) with a nanodisc (ND) provide another siRNA delivery vehicle. ND consists of particles having high-density lipoprotein complexed with one or more multiple exogenic bioactive agents.…”

Section: Cationic Lipids For Sirna Deliverymentioning

confidence: 99%

Knocking Down Barriers: Advances in siRNA Delivery

et al. 2021

View full text Add to dashboard Cite

RNA interference (RNAi) has been emerged as an effective method to silence a particular gene utilizing a sequence‐specific mechanism for gene regulation. It induces target mRNA degradation leading to a lower illness‐inducing gene product. RNAi represent a conserved mechanism. Novel concept of highly specific silencing of genes was revolutionized by the introduction of short interfering RNA (siRNA).This helped to overcome the drawbacks of RNAi and proved out to be a safer and efficient method than its counterpart finding its way into the pharmaceutical industry. Clinical trials enhanced the possibility of siRNA delivery and yielded promising results for the treatment of a wide range of illnesses but mainly for intractable diseases like cancer, inflammatory diseases, and genetic disorders. siRNA delivery methods were instrumental in developing it as a therapeutic, of which lipid encapsulation crept its way, to be a better in vivo delivery mechanism as it could be formulated effectively, being biodegradable, and has a lower toxicity level. However, the therapeutic potential of siRNA remains hampered due to a lack of a viable delivery method, a lower accuracy in tissue specificityand cytotoxicity. Hence the therapeutic usage of the method is in its budding stage. This review re‐examines the principle of siRNA, challenges in its delivery, and some recent advancesto overcome the obstacles in order to improve siRNA delivery.

show abstract

DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells

Cited by 14 publications

References 41 publications

Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines

Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Knocking Down Barriers: Advances in siRNA Delivery

Contact Info

Product

Resources

About